Maven Securities LTD Has $436,000 Stock Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Maven Securities LTD reduced its stake in Bicara Therapeutics Inc. (NASDAQ:BCAX) by 50.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,000 shares of the company’s stock after selling 25,000 shares during the quarter. Maven Securities LTD’s holdings in Bicara Therapeutics were worth $436,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Spire Wealth Management acquired a new position in Bicara Therapeutics in the fourth quarter valued at approximately $31,000. BNP Paribas Financial Markets bought a new position in Bicara Therapeutics during the fourth quarter worth $32,000. Legal & General Group Plc bought a new position in Bicara Therapeutics during the fourth quarter worth $33,000. Summit Investment Advisors Inc. bought a new position in Bicara Therapeutics during the fourth quarter worth $35,000. Finally, Virtus ETF Advisers LLC bought a new position in Bicara Therapeutics during the fourth quarter worth $69,000.

Analysts Set New Price Targets

Several brokerages recently issued reports on BCAX. Wells Fargo & Company began coverage on shares of Bicara Therapeutics in a research note on Thursday, April 17th. They set an “underweight” rating and a $8.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Cantor Fitzgerald reissued an “overweight” rating and set a $13.01 target price on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Stifel Nicolaus set a $48.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Finally, HC Wainwright cut their target price on shares of Bicara Therapeutics from $45.00 to $44.00 and set a “buy” rating on the stock in a research note on Monday, April 7th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $32.43.

Bicara Therapeutics Trading Down 8.1%

Shares of BCAX stock opened at $13.04 on Wednesday. The firm has a 50-day moving average of $12.94 and a 200-day moving average of $15.46. Bicara Therapeutics Inc. has a one year low of $8.91 and a one year high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.28). On average, sell-side analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.